**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 57954

**Manuscript Type:** MINIREVIEWS

**Role of argon plasma coagulation in treatment of esophageal varices**

Song Y *et al*. Argon plasma coagulation in esophageal varices

Ying Song, Yuan Feng, Li-Hui Sun, Bo-Jiang Zhang, Hong-Juan Yao, Jing-Gui Qiao, Shu-Fen Zhang, Ping Zhang, Bin Liu

**Ying Song, Yuan Feng, Li-Hui Sun, Bo-Jiang Zhang, Hong-Juan Yao, Jing-Gui Qiao, Shu-Fen Zhang,** Department of Gastroenterology, Xi’an Gaoxin Hospital, Xi'an 710032, Shaanxi Province, China

**Ping Zhang, Bin Liu,** Department of Clinical Medical Affair, Erbe China Ltd., Shanghai 200336, China

**Author contributions:** Song Y, Feng Y, Sun LH and Liu B carried out the studies, participated in collecting the data, and drafted the manuscript; Qiao JG, Zhang SF, and Zhang P participated in manuscript design; Zhang BJ and Yao HJ searched the references and helped to draft the manuscript; all authors read and approved the final manuscript.

**Corresponding author: Ying Song, MSc, Research Associate,** Department of Gastroenterology, Xi’an Gaoxin Hospital, No. 16 South Tuanjie Road, Xi'an 710032, Shaanxi Province, China. song\_ying20@21cn.com

**Received:** June 30, 2020

**Revised:** August 13, 2020

**Accepted:** November 29, 2020

**Published online:** January 26, 2021

**Abstract**

With the development of endoscopic therapy, argon plasma coagulation (APC) has been widely used by endoscopists. It has many advantages, such as simple to operate, low cost, and minimal invasiveness. Because of its capability of lesion ablation and hemostasis, APC has several indications in the gastrointestinal tract. One of them is esophageal varices. The aim of this review is to summarize the research on APC in this field to provide a reference for clinical practice.

**Key Words:** Esophageal varices; Argon plasma coagulation; Clinical practice; Endoscopic therapy; Gastrointestinal tract; Minimally invasive

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Song Y, Feng Y, Sun LH, Zhang BJ, Yao HJ, Qiao JG, Zhang SF, Zhang P, Liu B. Role of argon plasma coagulation in treatment of esophageal varices. *World J Clin Cases* 2021; 9(3): 521-527

**URL:** https://www.wjgnet.com/2307-8960/full/v9/i3/521.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v9.i3.521

**Core Tip:** Considering the current relevant research results, argon plasma coagulation has considerable efficacy and safety in the treatment of esophageal varices.

**INTRODUCTION**

Cirrhosis and portal hypertension can cause varicose veins in different parts of the digestive tract, of which esophageal varices (EV) are most common. EV occur in 5% of cirrhotic patients without varicose veins after 1 year and 28% after 3 years, while 12% of patients with mild EV after 1 year and 31% after 3 years will progress to severe EV. It can be seen that during the process of liver cirrhosis, 50%-60% of patients will have EV[[1-3](#_ENREF_1)]. EV rupture hemorrhage is a common clinical critical illness and is featured as sudden onset, large amount of bleeding, rapid progression, and high mortality. It is a potentially fatal complication in patients with liver cirrhosis and the mortality rate is as high as 20%[[3](#_ENREF_3),[4](#_ENREF_4)].For patients with cirrhosis who have not been treated after diagnosis of EV, about 1/3 of patients would bleed for the first time in 2 years, of whom about 60% would re-bleed within 2 years[[5](#_ENREF_5)]. There are many hepatitis patients in China and cirrhosis combined with EV rupture bleeding seriously affects the prognosis of patients, causing a great psychological and economic burden on individuals, families, and society.

Upper gastrointestinal endoscopy is a preferred method for the diagnosis of EV rupture bleeding. Endoscopic treatment is also the main method for emergency hemostasis and prevention of re-bleeding in EV rupture. At present, the main methods of endoscopic treatment of EV included endoscopic variceal ligation (EVL), endoscopic injection sclerotherapy (EIS), and a combination of EVL and EIS. However, the recurrence rate after EVL was 21.3%-92% and the recurrence rate after EIS was 11%-24%. The traditional approach is to administer β-blockers after endoscopic treatment to reduce the recurrence of varicose veins, thereby reducing the rate of re-bleeding. However, some patients cannot tolerate or respond poorly to drugs, or have contraindications to use. For small EV, it is often impossible to perform effective ligation or sclerosis, so that varicose veins cannot be completely eradicated. Among the causes of EV recurrence, in addition to the persistent portal hypertension, failure to achieve complete eradication is also an important reason. In order to reduce recurrence and the bleeding rate, some guidelines emphasize that for varicose veins, complete eradication is possible, that is, after the basic eradication, the remaining small blood vessels are treated to achieve complete eradication, delay the recurrence of varicose veins, and further reduce the risk of bleeding as well as improve long-term efficacy.

At present, treatment methods for small and residual EV included endoscopic argon plasma coagulation (APC), photodynamic therapy, metal clip therapy, ligation, and additional sclerosis. Photodynamic therapy is a method for treating target tissues based on the cytotoxic effect of the photodynamic response of the photosensitizer. Its operation is cumbersome and costly and requires to be under dark for 3-7 d after treatment. Metal clip therapy uses metal clamps to clamp the small veins under the guidance of endoscopy and has a certain effect on the occlusion of the small veins, but the action site is limited with a risk of damaging the blood vessels. For the small tortuous residual small veins, it is often impossible to perform effective ligation or hardening and there is a risk of esophageal stenosis. Therefore, in clinical practice, the above methods are subject to certain restrictions. More and more studies have shown that treatment of EVs ≤ 0.3 cm by APC can promote mucosal fibrosis, and inhibit capillary hyperplasia and invasion of perforating veins, thereby reducing the recurrence of varicose veins and achieving complete eradication.

APC belongs to monopolar electrosurgery and is characterized by non-contact thermal coagulation. It uses argon gas, which is stable, non-toxic, and odorless inert. Under the action of high frequency electricity, the argon gas is ionized into an argon plasma beam. Then, the high-frequency current was applied to target tissue to achieve coagulation and a uniform and stable hemostatic effect. Based on its technical principle, APC generator usually has two main parts. One part is for argon and the other is for high frequency electricity. Due to its wide function, superficiality, easy operation, safety, and effectiveness, APC has been widely used in many gastrointestinal diseases, such as early cancer of the digestive tract, precancerous lesions, Barrett's esophagus, dilatation of the gastric antrum, and non-varicose gastrointestinal bleeding[[6-10](#_ENREF_6)]. The depth of APC treatment is generally 0.5-3.0 mm and it can seal blood vessels with a diameter of ≤ 0.3 cm, therefore it is reported that APC can also play a role in the treatment of EV. Nakamura *et al*[[11](#_ENREF_11)] treated EV using APC the first time. Since esophageal mucosal fibrosis is the key to the prevention of EV recurrence, subsequent studies will use APC as an adjunct to the combination of EVL and/or EIS to eradicate EV[[3](#_ENREF_3),[12](#_ENREF_12)].

The operation process of APC in the treatment of EV can be as follows[[13](#_ENREF_13)]: The APC catheter was inserted through the biopsy orifice under endoscopic direct vision, about 3-5 mm from the lesion. The flow rate of argon jet was 0.8-1.2 L/min and the power was 25-35 W. Coagulation treatment was performed every 1-3 s. The number of coagulations depended on the length of the lesion, the size of the local vascular network, the patient's tolerance, *etc.* The gas is sprayed along the blood vessel until the local tissue became white or burnt, the varicose veins disappeared, and the vascular network was blurred. Based on the LDRf classification as described by previous studies[[14](#_ENREF_14),[15](#_ENREF_15)],APC was first used in 2007 to treat EV with a diameter ≤ 0.3 cm[[13](#_ENREF_13),[16](#_ENREF_16)], and demonstrated high treatment safety. The aim of this review is to summarize these current research of APC in the treatment of EV and to discuss its clinical value and future development.

**APC COMBINED WITH EVL TREATMENT**

EVL achieves hemostasis through mechanically ligating varicose veins, which is one of the important ways to treat EV. The esophageal vein can be divided into four zones, gastric zone, palisade zone (PZ), perforating zone (Piz), and truncal zone. The principle of EVL in the treatment of EV is based on the esophageal venous drainage system, and it mainly ligates the PZ and Piz varicose veins to occlude and remove the submucosal veins in the PZ. Then, a thrombus was then formed, gradually blocking the deep and perforating veins[18]. Pathological studies have shown that EVL treatment can maintain the integrity of the muscular layer and ischemic necrosis was found within 1-4 d after the ligation area. The formed mucosal ulcers gradually re-epithelialized and then formed scar tissue, which made the blood vessels disappear[[17](#_ENREF_18),[18](#_ENREF_19)]. It is believed that EVL can quickly eliminate varicose veins and the operation is simple[[19](#_ENREF_18)], so it is widely advocated. However, because EVL cannot damage deep veins and perforating veins, studies have shown that the recurrence rate of esophageal varices after EVL can reach 21.3%-92% and the rates of complications are about 2%-31%. Common complications include chest pain, esophageal ulcers, difficulty swallowing, esophageal stenosis, *etc.*[[18](#_ENREF_19)]. A previous study has used APC for sequential treatment after EVL for the first time and showed that APC combined with EVL was superior to simple EVL, representing an effective method to achieve complete eradication of EV[[11](#_ENREF_11)]. A number of randomized controlled trials have shown (Tables 1 and 2) that sequential treatment with EVC after EVL can significantly reduce the recurrence rate of varicose veins and the rates of re-bleeding and death compared with EVL treatment alone[[11](#_ENREF_11),[13](#_ENREF_13),[19-21](#_ENREF_20)]. The rate of postoperative fever was higher in the combined treatment group than in the EVL group alone. A-meta analysis showed that EVL combined with APC may be the best choice to reduce the rates of re-bleeding and mortality[[22](#_ENREF_23)]. At present, it is suggested to perform APC treatment after 1-3 wk of EVL operation recovery, that is, the two sequential methods are used to reduce the incidence of postoperative esophageal stenosis[[20](#_ENREF_21)]. The incidence of difficulty swallowing seems higher after EVL combined with APC treatment in most studies as shown in Table 2. The main adverse events included varicose veins, recurrent bleeding, fever, difficulty swallowing, esophageal stenosis, and mortality.Nakamura *et al*[[11](#_ENREF_11)] reported that esophageal stenosis occurred in only one patient. The eradication course of EVL combined with APC treatment showed an increasing trend compared with EVL alone due to the addition of APC[[11](#_ENREF_11),[20](#_ENREF_21),[21](#_ENREF_22)]. Harras *et al*[[20](#_ENREF_21)] believed that it is safe and effective to perform APC treatment at a distance of 5 cm from the cardia of distal esophagus. However, the sample size of the research is small and further research is required to confirm the findings.

**APC COMBINED WITH EIS TREATMENT**

Because EVL is simple, safe, and does not require sclerosing agents, it is often regarded as the first-line treatment for EV. In contrast, EIS is mostly a selective treatment[[3](#_ENREF_3),[23](#_ENREF_25)]. However, most studies have shown that the recurrence of varicose veins after EIS is lower than that after EVL[[24](#_ENREF_26)]. The recurrence rate is about 11%-24% and the re-bleeding rate after EIS is about 4%-20%[[20](#_ENREF_21),[25](#_ENREF_27),[26](#_ENREF_28)]. Deguchi *et al*[[3](#_ENREF_3)] conducted a retrospective study comparing sequential APC treatment (62 cases) after EIS with EIS alone (124 cases) and showed that the recurrence rates were 9.7% and 11.3% after 1 year and 2 years in the combined treatment group, respectively, while they were 29.0% and 34.7% in the treatment alone group. The Kaplan-Meier curve showed that the recurrence rate in the combination treatment group was significantly lower without serious adverse events related to APC. Another study by Kondo *et al*[[27](#_ENREF_29)] showed that EIS combined with APC for the treatment of EV does not seem to have much effect on the portal pressure gradient. Two studies have shown that[[3](#_ENREF_3),[28](#_ENREF_30)] sequential APC treatment after EIS is safe and can prevent the recurrence of esophageal varices. The above studies preliminarily suggest that combined APC treatment after EIS can reduce the recurrence rate without obvious adverse reactions. But its actual clinical value still needs further verification by large cohort clinical studies.

**SIMPLE APC FOR EVS WITH A DIAMETER ≤ 0.3 CM**

EVL and EIS are the most common methods for the endoscopic treatment of EV, but the two methods can only target varicose veins > 0.3 cm in diameter[[15](#_ENREF_15)]. However, 5% of cirrhotic patients without varicose veins develop EV after 1 year and 28% after 3 years; and 12% of patients with mild EV after 1 year and 31% after 3 years progress to severe EV[[16](#_ENREF_16)]. Therefore, early diagnosis and treatment are essential for preventing EV progression. A previous study reviewed seven patients with APC treatment for LeD0.3Rf0 classification, whose relapse time was 4 mo to 17 mo, and there were no serious complications[[14](#_ENREF_14)]. In addition, previous studies have also shown that APC can effectively seal blood vessels with a diameter of ≤ 0.3 cm, thereby alleviating the recurrence of varicose veins[[17](#_ENREF_17)]. The study preliminarily confirmed that APC is safe and effective for the treatment of varicose veins with a diameter of ≤ 0.3 cm, but prospective research with large samples are still needed.

**PERSPECTIVES**

APC has been widely used in recent years and the technology is still improving. The setting parameters of APC devices from different manufacturers are slightly different. Several reports used APC 300/ICC 200 (Erbe, Germany) with the setting of 50-60 W and the flow rate of 1.5-2.0 L/min[[19](#_ENREF_20),[29](#_ENREF_31)]. However, APC 2 (Erbe, Germany) is now very common on the market and provides parameter settings including output power, argon flow rate, and mode. The new generation, APC 3 (Erbe, Germany), replaces the output power with the effect, and the number of adjustable gears is increased to 100 gears, which is more refined. Different parameters have different effects. Specifically, the factors that affect APC treatment efficacy include output power, duration, current intensity, argon flow rate, and the distance between the probe and the tissue. In order to eradicate the lesion, domestic endoscopists currently use 25-30 W output power for the treatment[[13](#_ENREF_13)], while foreign endoscopists often use higher output power (50-60 W) to treat precancerous lesions of the digestive tract, such as Barrett’s esophagus[[30](#_ENREF_32)]. However, higher power is easy to damage the muscular layer, resulting in esophageal stenosis. Therefore, hybrid-APC was developed (Erbe, Germany, Tubingen) in recent years. That is a novel multi-functional instrument, which integrates APC and needle-free submucosal injection, so as to reduce thermal damage of the muscle layer from ablation through creating a submucosal water cushion before APC ablation[[31](#_ENREF_33)]. So far, there has been no proof about the effect of difference of APC settings on EV and the treatment usually depends on the experience of endoscopists. Further studies about the application of different APC technology should be discussed, such as precise APC, pulse APC, and hybrid-APC.

**CONCLUSION**

Considering the current relevant research results, APC has considerable efficacy and safety in the treatment of EV. Its clinical application and characteristics can be summarized as follows: (1) APC can be used for ablation of varicose veins that meet Le D0.3 Rf0 classification with a good therapeutic effect, which can eradicate esophageal varicose veins very quickly and help to prolong the time to recurrence and expand the monitoring interval of endoscopic observation, thereby reducing the psychological burden of patients; (2) according to individual differences, patients with an EV diameter > 0.3 cm can choose EVL or EIS treatment, and postoperative combination therapy with APC is feasible to reduce the relapse rate; (3) since the coagulation depth of APC is limited to 3 mm, perforation is not likely to occur and there are no obvious complications; and (4) APC is non-contact coagulation, so it will not cause adhesion and secondary bleeding caused by adhesion. However, the above conclusions still need to be verified by large cohort clinical studies.

**REFERENCES**

1 **Berumen J**, Baglieri J, Kisseleva T, Mekeel K. Liver fibrosis: Pathophysiology and clinical implications. *Wiley Interdiscip Rev Syst Biol Med* 2020; e1499 [PMID: 32713091 DOI: 10.1002/wsbm.1499]

2 **Roehlen N**, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. *Cells* 2020; **9**: 875 [PMID: 32260126 DOI: 10.3390/cells9040875]

3 **Deguchi H**, Kato J, Maeda Y, Moribata K, Shingaki N, Niwa T, Inoue I, Maekita T, Iguchi M, Tamai H, Ichinose M. Argon plasma coagulation is effective for prevention of recurrent esophageal varices after endoscopic injection sclerotherapy: Single-center case-control study. *Dig Endosc* 2016; **28**: 42-49 [PMID: 26295791 DOI: 10.1111/den.12538]

4 **Merli M**, Nicolini G, Angeloni S, Rinaldi V, De Santis A, Merkel C, Attili AF, Riggio O. Incidence and natural history of small esophageal varices in cirrhotic patients. *J Hepatol* 2003; **38**: 266-272 [PMID: 12586291 DOI: 10.1016/s0168-8278(02)00420-8]

5 **Triantos C**, Kalafateli M. Endoscopic treatment of esophageal varices in patients with liver cirrhosis. *World J Gastroenterol* 2014; **20**: 13015-13026 [PMID: 25278695 DOI: 10.3748/wjg.v20.i36.13015]

6 **He S**, Liu X, Du G, Chen W, Ruan W. Clinical study of the use of gastroscopy as oral choledochoscopy. *Exp Ther Med* 2018; **16**: 1333-1337 [PMID: 30116382 DOI: 10.3892/etm.2018.6320]

7 **Garg S**, Aslam B, Nickl N. Endoscopic resolution and recurrence of gastric antral vascular ectasia after serial treatment with argon plasma coagulation. *World J Gastrointest Endosc* 2017; **9**: 263-266 [PMID: 28690769 DOI: 10.4253/wjge.v9.i6.263]

8 **Aritake T**, Takagi K, Nagano N, Kobayashi R, Maeda T, Kawai K, Kawai S, Kamiya S. Argon plasma coagulation for successful treatment of bile leakage after subtotal cholecystectomy. *Surg Case Rep* 2020; **6**: 111 [PMID: 32448980 DOI: 10.1186/s40792-020-00876-z]

9 **Kim B**, Kim BJ, Seo IK, Kim JG. Cost-effectiveness and short-term clinical outcomes of argon plasma coagulation compared with endoscopic submucosal dissection in the treatment of gastric low-grade dysplasia. *Medicine (Baltimore)* 2018; **97**: e0330 [PMID: 29642169 DOI: 10.1097/MD.0000000000010330]

10 **Uesato M**, Kono T, Akutsu Y, Murakami K, Kagaya A, Muto Y, Nakano A, Aikawa M, Tamachi T, Amagai H, Arasawa T, Muto Y, Matsubara H. Endoscopic occlusion with silicone spigots for the closure of refractory esophago-bronchiole fistula after esophagectomy. *World J Gastroenterol* 2017; **23**: 5253-5256 [PMID: 28811720 DOI: 10.3748/wjg.v23.i28.5253]

11 **Nakamura S**, Mitsunaga A, Murata Y, Suzuki S, Hayashi N. Endoscopic induction of mucosal fibrosis by argon plasma coagulation (APC) for esophageal varices: A prospective randomized trial of ligation plus APC vs. ligation alone. *Endoscopy* 2001; **33**: 210-215 [PMID: 11293751 DOI: 10.1055/s-2001-12804]

12 **Becq A**, Camus M, Rahmi G, de Parades V, Marteau P, Dray X. Emerging indications of endoscopic radiofrequency ablation. *United European Gastroenterol J* 2015; **3**: 313-324 [PMID: 26279839 DOI: 10.1177/2050640615571159]

13 **Kamal A**, Abd Elmoety AA, Hamza Y, Zeid A. Endoscopic Variceal Ligation followed by Argon Plasma Coagulation Against Endoscopic Variceal Ligation Alone: A Randomized Controlled Trial. *J Clin Gastroenterol* 2017; **51**: 49-55 [PMID: 27136962 DOI: 10.1097/mcg.0000000000000535]

14 **Nett A**, Binmoeller KF. Endoscopic Management of Portal Hypertension-related Bleeding. *Gastrointest Endosc Clin N Am* 2019; **29**: 321-337 [PMID: 30846156 DOI: 10.1016/j.giec.2018.12.006]

15 **Yang Q**, Zhao Y, Chen X, Tang P, Li L, Zhao J, Han Y, Wu D, An L, Zhang B, Zhou X, Liu L, Chi YW. Association Between Vein Diameters, Reflux Characteristics, and Clinical Severity in Patients with Chronic Venous Insufficiency in Northwest China. *J Vasc Surg Venous Lymphat Disord* 2020 epub ahead of print [PMID: 32730997 DOI: 10.1016/j.jvsv.2020.07.006]

16 **Mujtaba S**, Chawla S, Massaad JF. Diagnosis and Management of Non-Variceal Gastrointestinal Hemorrhage: A Review of Current Guidelines and Future Perspectives. *J Clin Med* 2020; **9**: 402 [PMID: 32024301 DOI: 10.3390/jcm9020402]

17 **Fuccio L**, Zagari RM, Serrani M, Eusebi LH, Grilli D, Cennamo V, Laterza L, Asioli S, Ceroni L, Bazzoli F. Endoscopic argon plasma coagulation for the treatment of gastric antral vascular ectasia-related bleeding in patients with liver cirrhosis. *Digestion* 2009; **79**: 143-150 [PMID: 19329853 DOI: 10.1159/000210087]

18 **Kapoor A**, Dharel N, Sanyal AJ. Endoscopic Diagnosis and Therapy in Gastroesophageal Variceal Bleeding. *Gastrointest Endosc Clin N Am* 2015; **25**: 491-507 [PMID: 26142034 DOI: 10.1016/j.giec.2015.03.004]

19 **Cipolletta L**, Bianco MA, Rotondano G, Marmo R, Meucci C, Piscopo R. Argon plasma coagulation prevents variceal recurrence after band ligation of esophageal varices: preliminary results of a prospective randomized trial. *Gastrointest Endosc* 2002; **56**: 467-471 [PMID: 12297759 DOI: 10.1067/mge.2002.127409]

20 **Harras F**, Sheta el S, Shehata M, El Saadany S, Selim M, Mansour L. Endoscopic band ligation plus argon plasma coagulation versus scleroligation for eradication of esophageal varices. *J Gastroenterol Hepatol* 2010; **25**: 1058-1065 [PMID: 20594219 DOI: 10.1111/j.1440-1746.2010.06265.x]

21 **Hamza I**, Mahmoud M, Labib S. The initial experience of safety and efficacy of argon plasma coagulation (APC) in the primary prevention of variceal bleeding. *Arab J Gastroenterol* 2012; **13**: 125-129 [PMID: 23122453 DOI: 10.1016/j.ajg.2012.08.008]

22 **Shi KQ**, Liu WY, Pan ZZ, Ling XF, Chen SL, Chen YP, Fan YC, Zheng MH. Secondary prophylaxis of variceal bleeding for cirrhotic patients: a multiple-treatments meta-analysis. *Eur J Clin Invest* 2013; **43**: 844-854 [PMID: 23725530 DOI: 10.1111/eci.12115]

23 **Turon F**, Casu S, Hernández-Gea V, Garcia-Pagán JC. Variceal and other portal hypertension related bleeding. *Best Pract Res Clin Gastroenterol* 2013; **27**: 649-664 [PMID: 24160925 DOI: 10.1016/j.bpg.2013.08.004]

24 **Gonzalo Bada N**, Suárez Parga JM, Hernández Cabrero T, Ponce Dorrego D, Zarauza Soto Y, Abadía Barnó M, Olveira Martín A, Novo Torres J, Rodríguez Díaz R, Fernández Rodríguez L, Mora Sanz P, Froilán Torres C. Hemodynamic changes after endoscopic variceal ligation: a cohort study. *Rev Esp Enferm Dig* 2020; **112**: 456-461 [PMID: 32450703 DOI: 10.17235/reed.2020.6656/2019]

25 **Svoboda P**, Kantorová I, Ochmann J, Kozumplík L, Marsová J. A prospective randomized controlled trial of sclerotherapy vs ligation in the prophylactic treatment of high-risk esophageal varices. *Surg Endosc* 1999; **13**: 580-584 [PMID: 10347295 DOI: 10.1007/s004649901045]

26 **Yuki M**, Kazumori H, Yamamoto S, Shizuku T, Kinoshita Y. Prognosis following endoscopic injection sclerotherapy for esophageal varices in adults: 20-year follow-up study. *Scand J Gastroenterol* 2008; **43**: 1269-1274 [PMID: 18609148 DOI: 10.1080/00365520802130217]

27 **Kondo T**, Maruyama H, Kiyono S, Sekimoto T, Shimada T, Takahashi M, Okugawa H, Yokosuka O, Kawahira H, Yamaguchi T. Eradication of esophageal varices by sclerotherapy combined with argon plasma coagulation: Effect of portal hemodynamics and longitudinal clinical course. *Dig Endosc* 2016; **28**: 152-161 [PMID: 26505617 DOI: 10.1111/den.12562]

28 **Matsui S**, Kudo M, Nakaoka R, Shiomi M, Kawasaki T. Comparison of argon plasma coagulation and paravariceal injection sclerotherapy with 1% polidocanol in mucosa-fibrosing therapy for esophageal varices. *J Gastroenterol* 2004; **39**: 397-399 [PMID: 15168254 DOI: 10.1007/s00535-003-1309-2]

29 **Ishimaru T**, Hatanaka A, Takazawa S, Konishi K, Iwanaka T. Development of new devices for translumenal endoscopic esophageal anastomosis. *J Laparoendosc Adv Surg Tech A* 2014; **24**: 268-273 [PMID: 24286283 DOI: 10.1089/lap.2013.0504]

30 **Manner H**, Rabenstein T, Pech O, Braun K, May A, Pohl J, Behrens A, Vieth M, Ell C. Ablation of residual Barrett's epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). *Endoscopy* 2014; **46**: 6-12 [PMID: 24353120 DOI: 10.1055/s-0033-1358813]

31 **Manner H**, May A, Kouti I, Pech O, Vieth M, Ell C. Efficacy and safety of Hybrid-APC for the ablation of Barrett's esophagus. *Surg Endosc* 2016; **30**: 1364-1370 [PMID: 26104794 DOI: 10.1007/s00464-015-4336-1]

**Footnotes**

**Conflict-of-interest statement:** There are no potential conflicts of interest to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** June 30, 2020

**First decision:** July 28, 2020

**Article in press:** November 29, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Enomoto H **S-Editor:** Liu M **L-Editor:** Wang TQ **P-Editor:** Liu JH

**Table 1 Basic characteristics of patients in clinical studies of “****argon plasma coagulation combined with endoscopic variceal ligation” *vs* “endoscopic variceal ligation alone” in treatment of esophageal varices**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Sample size (EVL+APC/EVL)** | **Age (EVL+APC/EVL) (mean ± SD)** | **Gender (male/female)** | **Liver function classification (EVL+APC/EVL)** | **Pathogenic factors (EVL+APC/EVL)** | **Varicose vein types (EVL+APC/EVL)** | **Follow-up (EVL+APC/EVL) (mean ± SD)** |
| Nakamura *et al*[11]. 2001 | Japan | 30/30 | 63.7 ± 5.8/60.8 ± 7.1 | EVL+APC: 22/8EVL: 21/9 | A: 9/7B: 17/18C: 4/5 | Virus: 25/26Alcohol: 4/4Others: 1/0 | F2: 19/17F3: 11/13 | 18.5 ± 6.8/15.8 ± 7.7 |
| Cipolletta *et al*[20]. 2002 | Italy | 16/14 | 62.8 ± 5.5/60.8 ± 6.2 | EVL+APC: 11/5EVL: 10/4 | Not mentioned | Not mentioned | F2: 10/9F3: 6/5 | 16.2 ± 5.8/16.5 ± 5.1 |
| Harras *et* *al*[20]. 2010 | Egypt | 50/50 | 50.64 ± 10.43/48.96 ± 10.27 | Not mentioned | A: 10/14B: 34/32C: 6/4 | Virus: 50/50Alcohol: 0/0Others: 0/0 | F2: 3/0F3: 47/50 | 16.3/17.4 |
| Hamza I *et al*[21]. 2012 | Egypt | 30/30 | 50.23 ± 2.095/50 ± 2.104 | EVL+APC: 16/14EVL: 18/12 | The two groups have the highest proportion of B grade, and there is no difference between the groups | Not mentioned | Post operative 3 mo:F0: 18/15F1: 12/15F2: 0/0 | Follow-up 3 mo and 6 mo |
| Kamal *et al*[13]. 2017 | Egypt | 20/20 | 48.4/47.8 | Not mentioned | A:12/12B: 6/6C: 2/2 | Virus: 20/20Alcohol: 0/0Others: 0/0 | Not mentioned | Not mentioned |

According to the Japanese Society of Portal Hypertension, F0: No varicose veins; F1: Linear small varicose veins; F2: Beaded medium Varicose veins; F3: Nodular or large varicose veins. APC: Argon plasma coagulation; EVL: Endoscopic esophageal varices ligation.

**Table 2 Clinical results of “argon plasma coagulation combined with endoscopic variceal ligation” *vs* “endoscopic variceal ligation alone” in treatment of esophageal varices**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Nakamura *et al*[11], 2001** | **Cipolletta *et al*[19], 2002** | **Harras *et al*[20], 2010** | **Hamza I *et al*[21], 2012** | **Kamal *et al*[13], 2017** |
| Group | EVL+APC | EVL | EVL+APC | EVL | EVL+APC | EVL | EVL+APC | EVL | EVL+APC | EVL |
| Sample size | 30 | 30 | 16 | 14 | 50 | 50 | 30 | 30 | 20 | 20 |
| Varicose veins | No recurrence 74.2% | No recurrence 49.6% | Recurrence 0% | Recurrence 42.8% | Recurrence 4% | Recurrence 28% | Post operative 6 moF0：16F1：14F2：0 | Post operative 6 moF0：10F1：19F2：1 | Recurrence 21.1% | Recurrence 68.4% |
| Recurrent bleeding | 3.3% | 6.7% | 0% | 7.2% | 2% | 8% | 0% | 0% | 0% | 10.5% |
| Fever | 63.3% | 33.3% | 81.3% | 0% | 34% | 8% | 6.7% | 6.7% | 60% | 15% |
| Difficulty swallowing | 30% | 26.7% | 50% | 0% | 36% | 12% | 3.3% | 3.3% | 35% | 30% |
| Esophageal stenosis | 3.3% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Mortality | 0% | 0% | 0% | 0% | 8% | 12% | 0% | 0% | 5% | 5% |
| Eradication course | 2.9 ± 0.6 | 2.5 ± 0.6 | Not mentioned | Not mentioned | 4.6 ± 0.7 | 3.7 ± 0.5 | 4.43 | 4.23 | Not mentioned | Not mentioned |

According to the Japanese Society of Portal Hypertension, F0: No varicose veins; F1: Linear small varicose veins; F2: Beaded medium Varicose veins; F3: Nodular or large varicose veins. APC: Argon plasma coagulation; EVL: Endoscopic esophageal varices ligation.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**